focus -WSS

focus

author：explore 2025-09-28 23:24:33 - browse：3

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Can CDC director Mandy Cohen drive consensus in Washington?

focus

WSS

J&J expands global access to TB drug amid advocacy campaign

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Leading voice in opioid treatment defends methadone clinic system

5 to watch: Tech startups trying to solve health care's staffing crisis

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

CVS Caremark has created a new ploy: the drug ‘rebate credit’

focus

focus

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Hollywood unions extend contract negotiations for actors

Gene editing the human germline: What are the risks?

Supreme Court strikes down use of affirmative action

Intermittent fasting comes with a heart risk? Not so fast

Heart attack and stroke risk calculators need revising

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Jerome Adams on the need for new antivirals for Covid

Leading voice in opioid treatment defends methadone clinic system

hotspot

Congress likely to miss an opportunity to fix drug shortages issue

Blood tests recalled over risk of missed heart attack diagnosis

Georgia court denies Trump's request to quash DA's 2020 election probe

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Stop the failed accountable care organization experiment

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

hotspot

focus

focus

hotspot